Sumatriptan

Imitrex, Tosymra (sumatriptan) is a small molecule pharmaceutical. Sumatriptan was first approved as Imitrex on 1997-08-26. It is used to treat cluster headache and migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1D and 5-hydroxytryptamine receptor 1B. In addition, it is known to target 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 6, and 5-hydroxytryptamine receptor 7. Imitrex's patents are valid until 2031-07-19 (FDA).